Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated:  4/30/2012
Local Institution
mi
from
Murray, UT
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated: 4/30/2012
Local Institution
mi
from
Murray, UT
Click here to add this to my saved trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated:  4/30/2012
Wasatch Clinical Research
mi
from
Salt Lake City, UT
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated: 4/30/2012
Wasatch Clinical Research
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated:  4/30/2012
Advanced Clinical Research
mi
from
Bingham, UT
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated: 4/30/2012
Advanced Clinical Research
mi
from
Bingham, UT
Click here to add this to my saved trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated:  4/30/2012
Local Institution
mi
from
Fairfax, VA
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated: 4/30/2012
Local Institution
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated:  4/30/2012
Burke Internal Medicine And Research
mi
from
Burke, VA
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated: 4/30/2012
Burke Internal Medicine And Research
mi
from
Burke, VA
Click here to add this to my saved trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated:  4/30/2012
Manassas Clinical Research Center
mi
from
Manassas, VA
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated: 4/30/2012
Manassas Clinical Research Center
mi
from
Manassas, VA
Click here to add this to my saved trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated:  4/30/2012
Hampton Roads Center For Clinical Research, Inc.
mi
from
Suffolk, VA
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated: 4/30/2012
Hampton Roads Center For Clinical Research, Inc.
mi
from
Suffolk, VA
Click here to add this to my saved trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated:  4/30/2012
Tidewater Integrated Medical Research
mi
from
Virginia Beach, VA
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated: 4/30/2012
Tidewater Integrated Medical Research
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated:  4/30/2012
Mylar Research
mi
from
Lakewood, WA
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated: 4/30/2012
Mylar Research
mi
from
Lakewood, WA
Click here to add this to my saved trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated:  4/30/2012
Sound Medical Research
mi
from
Port Orchard, WA
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated: 4/30/2012
Sound Medical Research
mi
from
Port Orchard, WA
Click here to add this to my saved trials
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated:  4/30/2012
Local Institution
mi
from
Spokane, WA
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
Status: Enrolling
Updated: 4/30/2012
Local Institution
mi
from
Spokane, WA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Carl T. Hayden VA Medical Center
mi
from
Phoenix, AZ
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Carl T. Hayden VA Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock
mi
from
No. Little Rock, AR
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Central Arkansas VHS Eugene J. Towbin Healthcare Ctr, Little Rock
mi
from
No. Little Rock, AR
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Loma Linda
mi
from
Loma Linda, CA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Loma Linda
mi
from
Loma Linda, CA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Palo Alto Health Care System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Connecticut Health Care System
mi
from
West Haven, CT
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Connecticut Health Care System
mi
from
West Haven, CT
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Bay Pines
mi
from
Bay Pines, FL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Bay Pines
mi
from
Bay Pines, FL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
North Florida/South Georgia Veterans Health System
mi
from
Gainesville, FL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Miami
mi
from
Miami, FL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Miami
mi
from
Miami, FL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
James A. Haley Veterans Hospital, Tampa
mi
from
Tampa, FL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
James A. Haley Veterans Hospital, Tampa
mi
from
Tampa, FL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Edward Hines,Jr., VA Hospital
mi
from
Hines, IL
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Richard Roudebush VA Medical Center, Indianapolis
mi
from
Indianapolis, IN
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Richard Roudebush VA Medical Center, Indianapolis
mi
from
Indianapolis, IN
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Iowa City
mi
from
Iowa City, IA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Iowa City
mi
from
Iowa City, IA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Maryland Health Care System, Baltimore
mi
from
Baltimore, MD
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Maryland Health Care System, Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Jamaica Plain Campus
mi
from
Boston, MA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Jamaica Plain Campus
mi
from
Boston, MA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Minneapolis
mi
from
Minneapolis, MN
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Kansas City MO
mi
from
Kansas City, MO
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Kansas City MO
mi
from
Kansas City, MO
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, St Louis
mi
from
St Louis, MO
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, St Louis
mi
from
St Louis, MO
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Omaha
mi
from
Omaha, NE
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Omaha
mi
from
Omaha, NE
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA New Jersey Health Care System, East Orange
mi
from
East Orange, NJ
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA New Jersey Health Care System, East Orange
mi
from
East Orange, NJ
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
New Mexico VA Health Care System, Albuquerque
mi
from
Albuquerque, NM
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
New Mexico VA Health Care System, Albuquerque
mi
from
Albuquerque, NM
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Western New York Healthcare System at Buffalo
mi
from
Buffalo, NY
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Western New York Healthcare System at Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Durham
mi
from
Durham, NC
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Durham
mi
from
Durham, NC
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Cleveland
mi
from
Cleveland, OH
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Portland
mi
from
Portland, OR
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Portland
mi
from
Portland, OR
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Pittsburgh Healthcare System
mi
from
Pittsburgh, PA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Pittsburgh Healthcare System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Pittsburgh Health Care System
mi
from
Pittsburgh, PA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Pittsburgh Health Care System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Ralph H Johnson VA Medical Center, Charleston
mi
from
Charleston, SC
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Ralph H Johnson VA Medical Center, Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
WJB Dorn Veterans Hospital, Columbia
mi
from
Columbia, SC
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
WJB Dorn Veterans Hospital, Columbia
mi
from
Columbia, SC
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center, Memphis
mi
from
Memphis, TN
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center, Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA Medical Center
mi
from
Nashville, TN
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
VA North Texas Health Care System, Dallas
mi
from
Dallas, TX
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
VA North Texas Health Care System, Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated:  5/2/2012
Zablocki VA Medical Center, Milwaukee
mi
from
Milwaukee, WI
VA NEPHRON-D: Diabetes iN Nephropathy Study
CSP #565 - Combination Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor for Treatment of Diabetic Nephropathy (VA NEPHRON-D Study)
Status: Enrolling
Updated: 5/2/2012
Zablocki VA Medical Center, Milwaukee
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Genetic Testing for Type 2 Diabetes
The Impact of Genetic Testing for Type 2 Diabetes on Health Behaviors
Status: Enrolling
Updated:  5/2/2012
VA Medical Center
mi
from
Durham, NC
Genetic Testing for Type 2 Diabetes
The Impact of Genetic Testing for Type 2 Diabetes on Health Behaviors
Status: Enrolling
Updated: 5/2/2012
VA Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes
A Phase 1, Single-center, Open-label, Randomized, Crossover Design Clinical Study in Subjects With Type 1 Diabetes Comparing Insulin Exposure & Response Following Inhalation of Technosphere Insulin Inhalation Powder Using the Gen2C Inhaler Vs Subcutaneous Rapid-Acting Analog
Status: Enrolling
Updated:  5/2/2012
Profil Institute for Clinical Research
mi
from
Chula Vista, CA
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes
A Phase 1, Single-center, Open-label, Randomized, Crossover Design Clinical Study in Subjects With Type 1 Diabetes Comparing Insulin Exposure & Response Following Inhalation of Technosphere Insulin Inhalation Powder Using the Gen2C Inhaler Vs Subcutaneous Rapid-Acting Analog
Status: Enrolling
Updated: 5/2/2012
Profil Institute for Clinical Research
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Metabolic Surgery Versus Medical Management for Resolution of Type II Diabetes
Metabolic Surgery vs. Medical Management for Resolution of Type II Diabetes: A Prospective Group Match Study
Status: Enrolling
Updated:  5/3/2012
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Metabolic Surgery Versus Medical Management for Resolution of Type II Diabetes
Metabolic Surgery vs. Medical Management for Resolution of Type II Diabetes: A Prospective Group Match Study
Status: Enrolling
Updated: 5/3/2012
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
Status: Archived
Updated:  5/3/2012
Clinical Research Facility
mi
from
Fair Oaks, CA
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
Status: Archived
Updated: 5/3/2012
Clinical Research Facility
mi
from
Fair Oaks, CA
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
Status: Archived
Updated:  5/3/2012
Clinical Research Facility
mi
from
Shelton, CT
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
Status: Archived
Updated: 5/3/2012
Clinical Research Facility
mi
from
Shelton, CT
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
Status: Archived
Updated:  5/3/2012
Clinical Research Facility
mi
from
St. Petersburg,, FL
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
A 12-week, Multi-Center, Randomized Double-Blind, Active Control Parallel Group Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
Status: Archived
Updated: 5/3/2012
Clinical Research Facility
mi
from
St. Petersburg,, FL